# UC Investments

> UC Investments is a VC fund backing Health Care, Biotechnology and Artificial Intelligence. See 16 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Total investments: 16
- Last investment: Jul 2026
- Lead investor: 19%
- Last updated: Aug 2026

UC Investments is a VC fund focused on Health Care and Biotechnology. UC Investments

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 5 | 31% |
| Biotechnology | 5 | 31% |
| Artificial Intelligence | 4 | 25% |
| Machine Learning | 3 | 19% |
| Medical | 2 | 13% |

20 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 4 | 25% |
| Series B | 4 | 25% |
| Seed | 2 | 13% |
| Series D | 1 | 6% |
| Series E | 1 | 6% |

8 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 10 | 63% |
| Canada | 1 | 6% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Qolab | Qolab mission is to build high quality qubits by leveraging the most advanced semiconductor manufacturing processes. | $54.2M | Series B | Jul 02, 2026 |  |
| Qubic Technologies | Qubic Technologies is a manufacturer of quantum microwave transmitters and receivers for remote sensing and communication. | $2.5M | Seed | Jun 23, 2026 |  |
| Prenosis | Prenosis Inc. is a health tech innovator devoted to ushering in a new era of precision diagnostics in acute care using artificial intelligence. Its ImmunixTM precision diagnostics platform leverages machine learning algorithms trained on deep biological data and broad clinical data to more holistically capture and illuminate the complex healthstates of patients. Its proprietary NOSISTM dataset is the largest and fastest growing hybrid biomarker-clinical dataset for sepsis care. The Sepsis ImmunoScoreTM diagnostic on the ImmunixTM platform has the potential to save thousands of lives and billions of dollars in healthcare spending annually. | $20M | Series A | Jan 29, 2026 |  |
| Arena | LM Arena provides a platform for testing AI models. LM Arena serves as an essential resource for researchers and developers worldwide. As the AI field expands, the importance of reliable benchmarking tools like LM Arena remains undeniable. The company also operates Chatbot Arena, a specialized service for evaluating artificial intelligence systems. | $150M | Series A | Jan 06, 2026 |  |
| Arena | LM Arena provides a platform for testing AI models. LM Arena serves as an essential resource for researchers and developers worldwide. As the AI field expands, the importance of reliable benchmarking tools like LM Arena remains undeniable. The company also operates Chatbot Arena, a specialized service for evaluating artificial intelligence systems. | $100M | Seed | May 21, 2025 |  |
| Neurona Therapeutics | Neurona Therapeutics is a pre-clinical stage biotechnology company that was founded by four neuroscientists and stem cell pioneers at The University of California, San Francisco. They are focused on the discovery and development of cell-based therapies to treat intractable neurological disease. Its initial aim is to generate therapeuticcompositions of a specific type of nerve cell (or neuron) for targeted delivery into the injured nervous system. Based on nearly two decades of research, they believe that particular subpopulations of neurons have the unique ability to integrate and repair dysregulated neural circuits. Its talented team of scientists, scientific advisors, and board directors is working to accelerate breakthrough treatments for patients with significant unmet medical needs. | $102M |  | Apr 03, 2025 |  |
| Neurona Therapeutics | Neurona Therapeutics is a pre-clinical stage biotechnology company that was founded by four neuroscientists and stem cell pioneers at The University of California, San Francisco. They are focused on the discovery and development of cell-based therapies to treat intractable neurological disease. Its initial aim is to generate therapeuticcompositions of a specific type of nerve cell (or neuron) for targeted delivery into the injured nervous system. Based on nearly two decades of research, they believe that particular subpopulations of neurons have the unique ability to integrate and repair dysregulated neural circuits. Its talented team of scientists, scientific advisors, and board directors is working to accelerate breakthrough treatments for patients with significant unmet medical needs. | $102M | Series F | Apr 03, 2025 |  |
| Eikon Therapeutics | Eikon Therapeutics is a biopharmaceutical company that focuses on developing innovative technologies for drug discovery. The company utilizes advanced live-cell resolution microscopy and engineering to identify and create new therapeutic candidates. Eikon Therapeutics aims to enhance the understanding of biological processes at a cellular level,supporting targeted treatment development. The company’s approach integrates biology, engineering, and chemistry to streamline the drug discovery process. Through its proprietary platforms, Eikon Therapeutics seeks to advance clinical programs and expand its pipeline of potential medications. | $350.7M | Series D | Feb 26, 2025 |  |
| Horizon Surgical Systems | Horizon Surgical Systems specializes in the development of innovative technologies for microsurgery, focusing on robotics, medical imaging, and artificial intelligence. The company is dedicated to transforming the field of surgical ophthalmology by creating a novel, AI-driven, and imaging-guided surgical robotic system. This initiative aims toenhance the precision and effectiveness of microsurgical procedures, thereby improving patient outcomes. Horizon Surgical Systems is actively engaged in research and development to push the boundaries of what is possible in microsurgery, leveraging the latest advancements in technology to meet the evolving needs of healthcare professionals and patients. | $30M | Series A | Oct 16, 2024 |  |
| Digestiva | Digestiva develops the nutritional, sensory, and physiological properties of food and feed proteins with targeted biocatalysts. | $18.4M | Series A | Jul 15, 2024 |  |

10 of 16 investments shown.

## Co-investors
- [The Column Group](https://shizune.co/investors/profile/the-column-group) — VC Fund, 8 deals together
- [Lightspeed Venture Partners](https://shizune.co/investors/profile/lightspeed-venture-partners) — VC Fund, 6 deals together
- [Schroders Capital](https://shizune.co/investors/profile/schroders-capital) — VC Fund, 4 deals together
- [T. Rowe Price](https://shizune.co/investors/profile/t-rowe-price) — VC Fund, 4 deals together
- [Alexandria Venture Investments](https://shizune.co/investors/profile/alexandria-venture-investments) — VC Fund, 3 deals together
- [Andreessen Horowitz](https://shizune.co/investors/profile/andreessen-horowitz) — VC Fund, 3 deals together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does UC Investments invest in?

UC Investments invests primarily in Health Care, Biotechnology and Artificial Intelligence startups, most often at Series A and Series B stage. Most of the 16 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did UC Investments last invest?

The most recent investment recorded for UC Investments closed in Jul 2026. Shizune tracks 16 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co